These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 23253680)

  • 21. Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase 2/3 study in Europe in patients with primary immunodeficiencies.
    Borte M; Kriván G; Derfalvi B; Maródi L; Harrer T; Jolles S; Bourgeois C; Engl W; Leibl H; McCoy B; Gelmont D; Yel L
    Clin Exp Immunol; 2017 Jan; 187(1):146-159. PubMed ID: 27613250
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Subcutaneous immunoglobulin: rapid push vs. infusion pump in pediatrics.
    Shapiro RS
    Pediatr Allergy Immunol; 2013 Feb; 24(1):49-53. PubMed ID: 23331529
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of intravenous immunoglobulin G (IVIG).
    Looney RJ; Huggins J
    Best Pract Res Clin Haematol; 2006; 19(1):3-25. PubMed ID: 16377538
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Behavior abnormality following intravenous immunoglobulin treatment in patients with primary antibody deficiencies.
    Saroukhani S; Aghamohammadi A; Mahmoudi-Gharaei J; Abolhassani H; Cheraghi T; Imanzaeh A; Moazzami K; Parvaneh N; Rezaei N
    Hum Psychopharmacol; 2010 Jul; 25(5):419-22. PubMed ID: 20589928
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of Hizentra(®) in patients with primary immunodeficiency after a dose-equivalent switch from intravenous or subcutaneous replacement therapy.
    Jolles S; Bernatowska E; de Gracia J; Borte M; Cristea V; Peter HH; Belohradsky BH; Wahn V; Neufang-Hüber J; Zenker O; Grimbacher B
    Clin Immunol; 2011 Oct; 141(1):90-102. PubMed ID: 21705277
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Subcutaneous immunoglobulin replacement therapy with Hizentra, the first 20% SCIG preparation: a practical approach.
    Jolles S; Sleasman JW
    Adv Ther; 2011 Jul; 28(7):521-33. PubMed ID: 21681653
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies.
    Canessa C; Iacopelli J; Pecoraro A; Spadaro G; Matucci A; Milito C; Vultaggio A; Agostini C; Cinetto F; Danieli MG; Gambini S; Marasco C; Trizzino A; Vacca A; De Mattia D; Martire B; Plebani A; Di Gioacchino M; Gatta A; Finocchi A; Licciardi F; Martino S; De Carli M; Moschese V; Azzari C
    Int J Immunopathol Pharmacol; 2017 Mar; 30(1):73-82. PubMed ID: 27927705
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety of intravenous immunoglobulin (IVIG) therapy.
    Katz U; Achiron A; Sherer Y; Shoenfeld Y
    Autoimmun Rev; 2007 Mar; 6(4):257-9. PubMed ID: 17317619
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The safety profile of home infusion of intravenous immunoglobulin in patients with neuroimmunologic disorders.
    Souayah N; Hasan A; Khan HM; Yacoub HA; Jafri M
    J Clin Neuromuscul Dis; 2011 Jun; 12 Suppl 4():S1-10. PubMed ID: 22361589
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Improved quality of life, immunoglobulin G levels, and infection rates in patients with primary immunodeficiency diseases during self-treatment with subcutaneous immunoglobulin G.
    Berger M; Murphy E; Riley P; Bergman GE;
    South Med J; 2010 Sep; 103(9):856-63. PubMed ID: 20689467
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adverse reactions of intravenous immunoglobulin.
    Al-Wahadneh AM; Khriesat IA; Kuda EH
    Saudi Med J; 2000 Oct; 21(10):953-6. PubMed ID: 11369961
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Frequency of adverse events associated with intravenous immunoglobulin therapy in patients with pemphigus or pemphigoid.
    Gürcan HM; Ahmed AR
    Ann Pharmacother; 2007 Oct; 41(10):1604-10. PubMed ID: 17785614
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adverse reactions of prophylactic intravenous immunoglobulin; a 13-year experience with 3004 infusions in Iranian patients with primary immunodeficiency diseases.
    Dashti-Khavidaki S; Aghamohammadi A; Farshadi F; Movahedi M; Parvaneh N; Pouladi N; Moazzami K; Cheraghi T; Mahdaviani SA; Saghafi S; Heydari G; Abdollahzade S; Rezaei N
    J Investig Allergol Clin Immunol; 2009; 19(2):139-45. PubMed ID: 19476018
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and efficacy of subcutaneous human immunoglobulin in children with primary immunodeficiency.
    Fasth A; Nyström J
    Acta Paediatr; 2007 Oct; 96(10):1474-8. PubMed ID: 17850391
    [TBL] [Abstract][Full Text] [Related]  

  • 35. IgG anti-IgA antibodies in paediatric antibody-deficient patients receiving intravenous immunoglobulin.
    Torabi Sagvand B; Mirminachi B; Abolhassani H; Shokouhfar T; Keihanian T; Amirzargar A; Mahdaviani A; Aghamohammadi A
    Allergol Immunopathol (Madr); 2015; 43(4):403-8. PubMed ID: 25201762
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy, safety and pharmacokinetics of a new 10% normal human immunoglobulin for intravenous infusion, BT595, in children and adults with primary immunodeficiency disease.
    Kriván G; Borte M; Harris JB; Lumry WR; Aigner S; Lentze S; Staiger C
    Vox Sang; 2022 Oct; 117(10):1153-1162. PubMed ID: 35944615
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An open, prospective trial investigating the pharmacokinetics and safety, and the tolerability of escalating infusion rates of a 10% human normal immunoglobulin for intravenous infusion (IVIg), BT090, in patients with primary immunodeficiency disease.
    Kriván G; Königs Ch; Bernatowska E; Salama A; Wartenberg-Demand A; Sonnenburg C; Linde R
    Vox Sang; 2015 Oct; 109(3):248-56. PubMed ID: 25953213
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inpatient paediatric use of intravenous immunoglobulin at an academic medical centre.
    Dashti-Khavidaki S; Khalili H; Farshadi F; Aghamohammadi A; Movahedi M; Hajibabaei M
    Singapore Med J; 2008 Feb; 49(2):147-9. PubMed ID: 18301844
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Not all intravenous immunoglobulin preparations are equally well tolerated.
    Feldmeyer L; Benden C; Haile SR; Boehler A; Speich R; French LE; Hofbauer GF
    Acta Derm Venereol; 2010 Sep; 90(5):494-7. PubMed ID: 20814625
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America.
    Suez D; Stein M; Gupta S; Hussain I; Melamed I; Paris K; Darter A; Bourgeois C; Fritsch S; Leibl H; McCoy B; Gelmont D; Yel L
    J Clin Immunol; 2016 Oct; 36(7):700-12. PubMed ID: 27582171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.